Rezistentnost' Helicobacter pylori k komponentam eradikatsionnoy terapii i puti ee preodoleniya


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article reflects the current situation of growth of resistance of H. pylori to the main drugs included in the scheme of eradication therapy and, therefore, reduction of the effectiveness of treatment. The authors examine in detail the mechanisms of microbial resistance to antibiotics and provide ways to its overcoming.

Full Text

Restricted Access

References

  1. Georgopoulos S.D., Papastergiou V., Karatapanis S. Helicobacter pylori eradication therapies in the era of increasing antibiotic resistance: A paradigm shift to improved efficacy. Gastroenterol. Res. Pract. 2012;2012:757926.
  2. Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Антибиотикорезистентность Helicobacter pylori: от клинического значения до молекулярных механизмов. Лечащий врач. 2014;2:34-40.
  3. Megraud F.H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53:1374-84.
  4. De Francesco V., lerardi E., Hassan C., et al. Helicobacter pylori therapy: Present and future. World J. Gastrointest. Pharmacol. Ther. 2012;3(4):68-73.
  5. Elviss N.C., Owen R.J., Breathnach A., et al. Helicobacter pylori antibiotic-resistance patterns and risk factors in adult dyspeptic patients from ethnic diverse populations in central and south London during 2000. J. Med. Microbiol. 2005;4:567-74.
  6. Perez Aldana L., Kato M., Nakagawa S., et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter. 2002;7:306-09.
  7. Megraud F., Coenen S., Versporten A., et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62(1):34-42.
  8. Boyanova L., Ilieva J., Gergova G., et al. Numerous risk factors for Helicobacter pylori antibiotic resistance revealed by extended anamnesis: a Bulgarian study. J. Med. Microbiol. 2012;61(Pt. 1):85-93.
  9. Iwa czak F., Iwa czak B. Treatment of Helicobacter pylori infection in the aspect of increasing antibiotic resistance. Adv. Clin. Exp. Med. 2012; 21(5):671-80.
  10. Malfertheiner P., Megraud F., O'Morain C., et al. Management of Helicobacter pylori infection: the Maastricht IV. Florence Consensus Report. Gut. 2012;61(7):646-64.
  11. lerardi E., Giorgio F., Losurdo G., et al. How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography? World J. Gastroenterol. 2013; 19(45):8168-80.
  12. De Francesco V., Giorgio F., Hassan C., et al. Worldwide H. pylori antibiotic resistance: a systematic review. J. Gastrointestin. Liver Dis. 2010;19: 409-14.
  13. Gao W., Cheng H., Hu F., et al. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter 2010; 15:460-66.
  14. Huang-Ming Hu, Chi-Hsing Ou, Fu-Chen Kuo, et al. Geographical Difference in Primary Antimicrobial Resistance Pattern of Helicobacter pylori Clinical Isolates From Taiwan Patients During 2008-2013: Multicentric Study. Gastroenterology. 2014;5(146), Supp. 1:S-399.
  15. Camargo M.C., Garcia A., Riquelme A., et al. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am. J. Gastroenterol. 2014; 109:485-95.
  16. Самсонов A.A. Антибиотики схем эрадикации Helicobacter pylori. Чем мы ограничены в выборе препаратов? Росс. журн. гастроэнтерол., гепатол., колопрокт. 2008;4:63-8.
  17. Maev I., Andreev D., Kucheryavyi Yu., et al. Molecular mechanisms of Helicobacter pylori antibiotic resistance. Archiv. Euro. Medica. 2013;3(2):27-9.
  18. Wu W., Yang Y., Sun G. Recent Insights into Antibiotic Resistance in Helicobacter pylori Eradication. Gastroenterol. Res. Pract. 2012;5:723183.
  19. Francesco V.D., Zullo A., Hassan C., et al. Mechanisms of Helicobacter pylori antibiotic resistance: An updated appraisal. World J. Gastrointest. Pathophysiol. 2011;2(3):35-41.
  20. Glupczynski Y., Megraud F., Lopez-Brea M., et al. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis. 2001;20:820-23.
  21. Исаева Г.Ш. Резистентность H. pylori к антибактериальным препаратам и методы ее определения. Клин. микробиол. и антимикроб. химиотер. 2010;1:57-66.
  22. Барышникова Н.В., Денисова Е.В., Корниенко Е.А. и др. Эпидемиологическое исследование резистентности Helicobacter pylori к кларитромицину у жителей Санкт-Петербурга с язвенной болезнью. Экспер. и клин. гастроэнтерол. 2009;5:73-6.
  23. Осипенко М.Ф., Бикбулатова Е.А., Шакалите Ю.Д. и др. Резистентность Helicobacter pylori к кларитромицину в Новосибирске. Росс. журн. гастроэнтерол, гепатол, колопроктол. 2012;5(Прил. 40):36.
  24. Перфилова К.М., Неумоина Н.В., Неумоина М.В. и др. Изучение резистентности H. pylori к макролидам у больных с хроническими заболеваниями желудка и двенадцатиперстной кишки. Росс. журн. гастроэнтерол, гепатол, колопроктол. 2012;5(Прил. 40):37.
  25. Лазебник Л.Б., Рустамов М.Н. Резистентность к кларитромицину при эрадикации HP у больных дуоденальной язвой. Тез. докл. XII съезда Научного общества гастроэнтерологов России «Классическая и прикладная гастроэнтерология». М., 2012. С. 20.
  26. Rimbara E., Fischbach L.A., Graham D.Y. Optimal therapy for Helicobacter pylori infections. Nat. Rev. Gastroenterol. Hepatol. 2011;8(2):79-88.
  27. Marais A., Bilardi C., Cantet F., et al. Characterization of the genes rdxA and frxA involved in metronidazole resistance in Helicobacter pylori. Res. Microbiol. 2003; 154(2): 13 7-44.
  28. Кудрявцева Л.В. Состояние антибиотикорезистентности Helicobacter pylori в России. Эксп. клин. гастроэнтерол. 2003;3:4-5.
  29. Цуканов В.В., Штыгашева О.В., Баркалов С.В. Эпидемиология язвенной болезни (монография). Красноярск, 2004;198.
  30. Gerrits M.M., Godoy A.P., Kuipers E.J., et al. Multiple mutations in or adjacent to the conserved penicillin-binding protein motifs of the penicillin-binding protein 1A confer amoxicillin resistance to Helicobacter pylori. Helicobacter. 2006;11(3):181-87.
  31. Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Клинико-молекулярные аспекты резистентности Helicobacter pylori к антибактериальным препаратам. Медицинский совет. 2013;10:11-5.
  32. Wu J.Y., Kim J.J., Reddy R., et al. Tetracycline-resistant clinical Helicobacter pylori isolates with and without mutations in 16S rRNA-encoding genes. Antimicrob. Agents. Chemother. 2005;49:578-83.
  33. Perna F., Zullo A., Ricci C., et al. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig. Liver. Dis. 2007;39(11):1001-5.
  34. Nishizawa T., Suzuki H., Nakagawa I., et al. Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication. J. Gastroenterol. Hepatol. 2008;23(Suppl. 2): S167-70.
  35. Bogaerts P., Berhin C., Nizet H., et al. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter. 2006;11:441-45.
  36. Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Актуальные возможности оптимизации антихеликобактерной терапии. Лечащий врач. 2014;4:73-9.
  37. Villoria A., Garcia P., Calvet X., et al. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. 2008;28(7):868-77.
  38. Кучерявый Ю.А., Баркалова Е.В. Двойные дозы ингибиторов протонной помпы - путь повышения эффективности тройной антихеликобактерной терапии первой линии. Лечебное дело. 2012;1:36-42.
  39. Manes G., Pieramico O., Perri F., et al. Twice daily standard dose of omeprazole achieves the necessary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy. Dig. Dis. Sci. 2005;50(3):443-48.
  40. McNicholl A.G., Linares P.M., Nyssen O.P., et al. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 2012;36(5):414-25.
  41. Maev I.V., Andreev D.N., Kucheryavyi Yu.A., et al. Host factors influencing the eradication rate of Helicobacter pylori. World Appl. Sci. J. 2014; 30:134-40.
  42. Yang J.C., Lu C.W., Lin C.J. Treatment of Helicobacter pylori infection: current status and future concepts. World J. Gastroenterol. 2014;20(18):5283-93.
  43. Kuo C.H., Lu C.Y., Shih H.Y., et al. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J. Gastroenterol. 2014;20(43):16029-36.
  44. Tang H.L., Li Y., Hu Y.F., et al. Recent Insights into Antibiotic Resistance in Helicobacter pylori Eradication. Gastroenterol. Res. Pract. 2012;5:723183.
  45. Xie H.G., Zhai S.D. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS One. 2013;8:e62162.
  46. Williamson R., Pipkin G.A. Does bismuth prevent antimicrobial resistance of Helicobacter pylori? In: Helicobacter Pylori. Basic Mechanisms to Clinical Cure 1998. Ed. by R.H. Hunt, G.N.J. Tytgat. Dordrecht; Boston; London, 1998. P. 416-25.
  47. Sun Q., Liang X., Zheng Q., et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter. 2010;15(3):233-38.
  48. Gatta L., Vakil N., Vaira D., et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013;7(347):f4587.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies